CCG1423 is primarily used in biomedical research as a potent inhibitor of the Rho/MRTF-SRF signaling pathway, which plays a key role in cancer cell migration and metastasis. It has shown promise in suppressing the spread of prostate and other solid tumor cells by blocking the nuclear translocation of MRTF transcription co-activators. This compound is widely applied in studies focused on understanding cell motility, cytoskeletal dynamics, and gene expression regulation linked to tumor progression. Due to its ability to interfere with pathways involved in fibrosis and inflammation, CCG1423 is also explored in preclinical models of fibrotic diseases and cardiovascular conditions. Its selectivity makes it a valuable tool for probing SRF-dependent transcription without affecting other major signaling pathways.